- Home
- DRUG vs III Comparison
DRUG vs III Comparison
Compare DRUG & III Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRUG
- III
- Stock Information
- Founded
- DRUG 2019
- III 2006
- Country
- DRUG United States
- III United States
- Employees
- DRUG N/A
- III N/A
- Industry
- DRUG Pharmaceuticals and Biotechnology
- III Professional Services
- Sector
- DRUG Health Care
- III Consumer Discretionary
- Exchange
- DRUG Nasdaq
- III Nasdaq
- Market Cap
- DRUG 233.2M
- III 227.5M
- IPO Year
- DRUG N/A
- III 2007
- Fundamental
- Price
- DRUG $27.31
- III $4.53
- Analyst Decision
- DRUG Strong Buy
- III Buy
- Analyst Count
- DRUG 6
- III 1
- Target Price
- DRUG $83.25
- III $5.50
- AVG Volume (30 Days)
- DRUG 19.6K
- III 173.6K
- Earning Date
- DRUG 08-13-2025
- III 08-04-2025
- Dividend Yield
- DRUG N/A
- III 3.96%
- EPS Growth
- DRUG N/A
- III N/A
- EPS
- DRUG N/A
- III 0.16
- Revenue
- DRUG N/A
- III $242,899,000.00
- Revenue This Year
- DRUG N/A
- III N/A
- Revenue Next Year
- DRUG N/A
- III $5.08
- P/E Ratio
- DRUG N/A
- III $30.27
- Revenue Growth
- DRUG N/A
- III N/A
- 52 Week Low
- DRUG $0.93
- III $2.92
- 52 Week High
- DRUG $79.02
- III $5.05
- Technical
- Relative Strength Index (RSI)
- DRUG 41.95
- III 51.34
- Support Level
- DRUG $27.69
- III $4.71
- Resistance Level
- DRUG $28.74
- III $4.83
- Average True Range (ATR)
- DRUG 1.29
- III 0.13
- MACD
- DRUG 0.14
- III -0.04
- Stochastic Oscillator
- DRUG 39.29
- III 18.96
About DRUG Bright Minds Biosciences Inc.
Bright Minds Biosciences Inc is focused on developing novel transformative treatments for neuropsychiatric disorders, epilepsy, and pain. The company has a portfolio of next-generation serotonin agonists designed to target neurocircuit abnormalities that are responsible for difficult to treat disorders such as resistant epilepsy, treatment resistant depression, PTSD, and pain. The company's drugs have been designed to potentially retain the powerful therapeutic aspects of psychedelic and other serotonergic compounds, while minimizing the side effects, thereby creating superior drugs to first-generation compounds, such as psilocybin.
About III Information Services Group Inc.
Information Services Group Inc is a U.S.-based technology insight, market intelligence, and advisory services firm. It principally offers digital transformation services, such as automation and cloud & data analytics; managed governance; network carrier services; technology plan and operations design; changes management; market intelligence & technology research and analysis. It operates in one segment, fact-based sourcing advisory services. Its geographical segments are the Americas, Europe, and Asia-pacific, out of which maximum revenue is derived from Americas.